GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pieris Pharmaceuticals Inc (NAS:PIRS) » Definitions » E10

Pieris Pharmaceuticals (Pieris Pharmaceuticals) E10 : $-43.89 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pieris Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Pieris Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-3.950. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-43.89 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-31), Pieris Pharmaceuticals's current stock price is $10.5999. Pieris Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-43.89. Pieris Pharmaceuticals's Shiller PE Ratio of today is .


Pieris Pharmaceuticals E10 Historical Data

The historical data trend for Pieris Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pieris Pharmaceuticals E10 Chart

Pieris Pharmaceuticals Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -42.72

Pieris Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.32 -41.30 -42.54 -42.72 -43.89

Competitive Comparison of Pieris Pharmaceuticals's E10

For the Biotechnology subindustry, Pieris Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pieris Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Pieris Pharmaceuticals's Shiller PE Ratio falls into.



Pieris Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pieris Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.95/131.7762*131.7762
=-3.950

Current CPI (Mar. 2024) = 131.7762.

Pieris Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.036 100.560 -0.047
201409 -0.080 100.428 -0.105
201412 -0.710 99.070 -0.944
201503 -10.400 99.621 -13.757
201506 -9.600 100.684 -12.565
201509 -8.000 100.392 -10.501
201512 -5.600 99.792 -7.395
201603 -8.000 100.470 -10.493
201606 -11.518 101.688 -14.926
201609 -11.200 101.861 -14.489
201612 -12.800 101.863 -16.559
201703 -15.200 102.862 -19.473
201706 -18.400 103.349 -23.461
201709 -12.800 104.136 -16.197
201712 14.400 104.011 18.244
201803 -13.600 105.290 -17.021
201806 -0.301 106.317 -0.373
201809 -8.800 106.507 -10.888
201812 -16.800 105.998 -20.886
201903 -16.000 107.251 -19.659
201906 -19.200 108.070 -23.412
201909 -4.000 108.329 -4.866
201912 -4.800 108.420 -5.834
202003 -5.600 108.902 -6.776
202006 -7.200 108.767 -8.723
202009 -20.800 109.815 -24.960
202012 -20.800 109.897 -24.941
202103 -5.600 111.754 -6.603
202106 -20.000 114.631 -22.991
202109 -19.200 115.734 -21.861
202112 -10.400 117.630 -11.651
202203 -5.600 121.301 -6.084
202206 -11.200 125.017 -11.806
202209 -10.400 125.227 -10.944
202212 -8.800 125.222 -9.261
202303 -14.150 127.348 -14.642
202306 4.000 128.729 4.095
202309 -8.800 129.860 -8.930
202312 -3.200 129.419 -3.258
202403 -3.950 131.776 -3.950

Add all the adjusted EPS together and divide 10 will get our e10.


Pieris Pharmaceuticals  (NAS:PIRS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Pieris Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Pieris Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Pieris Pharmaceuticals (Pieris Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
225 Franklin Street, 26th Floor, Boston, MA, USA, 02110
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.
Executives
Ann Barbier director 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109
Peter A Kiener director 40 GUEST STREET, BOSTON MA 02135
Maya R. Said director C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Matthew L Sherman director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Christopher P Kiritsy director
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Shane Olwill officer: Chief Development Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Ahmed Mousa officer: Chief Business Officer 255 STATE STREET, 9TH FLOOR, C/O PIERIS PHARMACEUTICALS, INC., BOSTON MA 02109
Hitto Kaufmann officer: Chief Scientific Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Thomas Bures officer: Chief Financial Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Tim Demuth officer: Chief Medical Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Aquilo Capital Management, Llc 10 percent owner ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104

Pieris Pharmaceuticals (Pieris Pharmaceuticals) Headlines

From GuruFocus